TC Biopharm (Holdings) Plc (TCBP)
After hours:
| Previous close | 0.3545 |
| Open | 0.3600 |
| Bid | 0.3110 x 900 |
| Ask | 0.3290 x 1300 |
| Day's range | 0.3205 - 0.3600 |
| 52-week range | 0.3200 - 96.1000 |
| Volume | |
| Avg. volume | 478,104 |
| Market cap | 3.007M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.5500 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksTC BioPharm (TCBP) Falls Despite FDA Clearing IND for AML Drug
The FDA clears TC BioPharm's (TCBP) investigational new drug application seeking approval to begin a clinical study on its pipeline candidate, TCB008, for treating acute myeloid leukemia. Stock declines.
PR NewswireTC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia
TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced today that the FDA provides clearance on the Company's investigational new drug (IND) application for a Phase 1B study in relapse/refractory Acute Myeloid Leukemia (AML).
- PR Newswire
TC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB Results
TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announces today that the Company has successfully completed its Safety Cohort and received positive review from the Data Safety Monitoring Board (DSMB).
